3.67

1.38% 0.05

After Hours: 3.60 -0.07 -1.91%

Pyxis Oncology Inc (PYXS)

Overview News Price History Option Chain Financials Why PYXS Down? Discussions Forecast

Pyxis Oncology Inc stock is traded at $3.67, with a volume of 275.39K. It is up +1.38% in the last 24 hours and down -3.17% over the past month. Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Previous Close:

$3.62

Open:

$3.61

24h Volume:

275.39K

Relative Volume:

0.47

Market Cap:

$213.37M

Revenue:

Net Income/Loss:

$-73.79M

P/E Ratio:

-1.2923

EPS:

-2.84

Net Cash Flow:

$-77.44M

1W Performance:

+1.94%

1M Performance:

-3.17%

6M Performance:

-13.85%

1Y Performance:

+84.42%

1-Day Range:

$3.60

$3.70

1-Week Range:

$3.48

$3.82

52-Week Range:

$1.35

$6.85

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name

Pyxis Oncology Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(617) 221-9059

Address

321 HARRISON AVENUE, BOSTON

Employee

Twitter

Next Earnings Date

2024-08-11

Latest SEC Filings

PYXS's Discussions on Twitter

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-02-21	Initiated	BofA Securities	Neutral
Nov-02-21	Initiated	Credit Suisse	Outperform
Nov-02-21	Initiated	Jefferies	Buy

Pyxis Oncology Inc Stock (PYXS) Latest News

Sep 29, 2024

Rhumbline Advisers Takes Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Sep 29, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Analysts - Defense World

Sep 29, 2024

Sep 28, 2024

Blue Owl Capital Holdings LP Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat

Sep 28, 2024

Sep 25, 2024

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - PR Newswire

Sep 25, 2024

Sep 23, 2024

ShiftPixy stock plunges to 52-week low at $0.9 amid market challenges - Investing.com

Sep 23, 2024

Prepare Yourself for Liftoff: Pyxis Oncology Inc (PYXS) - SETE News

Sep 23, 2024

Sep 22, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Bank of New York Mellon Corp - MarketBeat

Sep 22, 2024

Sep 20, 2024

ShiftPixy, Inc. Announces Reverse Stock Split Effective Date - Business Wire

Sep 20, 2024

Are Pyxis Oncology Inc’shares a good deal? - US Post News

Sep 20, 2024

Sep 19, 2024

Pyxis Oncology (NASDAQ:PYXS) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat

Sep 19, 2024

Market Insights: Pyxis Oncology Inc (PYXS)’s Notable Gain of 1.39, Closing at 3.66 - The Dwinnex

Sep 19, 2024

Sep 17, 2024

Earth Science Tech (OTCMKTS:ETST) vs. Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Comparison - Defense World

Sep 17, 2024

Sep 13, 2024

Moment Of Truth Approaches For Pyxis Oncology (NASDAQ:PYXS) - Seeking Alpha

Sep 13, 2024

Sep 06, 2024

Pyxis Oncology : Morgan Stanley 22nd Annual Global Healthcare Conference - Marketscreener.com

Sep 06, 2024

Sep 04, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Sep 04, 2024

Sep 02, 2024